Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00343564 · ClinicalTrials.gov registry record · Phase 1
A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma
A Phase 1 study, sponsored by Cytokinetics.
- Completed
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
NCT00343564 is a Phase 1 study that has completed, run by Cytokinetics. The registered enrollment target is 68 participants.
The verdict
NCT00343564, a Phase 1 study, has completed, sponsored by Cytokinetics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
Study Summary
This study was an early-phase trial arranged into two phases. The Phase I portion was a dose-escalation study designed to assess the safety, tolerability and to identify the maximum tolerated dose of SB-743921 in patients with Non-Hodgkin Lymphoma and Hodgkin Lymphoma. Phase II was intended to assess the activity, safety and tolerability of SB-743921 in patients with Indolent and Aggressive Non-Hodgkin's Lymphomas exclusively. The Phase II portion of the study was not initiated.
Interventions
- DRUG SB-743921
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2006-04 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00343564
The ClinicalTrials.gov registry entry for NCT00343564 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 68 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cytokinetics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SB-743921 is the first listed.
NCT00343564 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00343564 about?
NCT00343564 is a clinical study titled "A Study of SB-743921 in Non-Hodgkin Lymphoma and Hodgkin Lymphoma". This study was an early-phase trial arranged into two phases. The Phase I portion was a dose-escalation study designed to assess the safety, tolerability and to identify the maximum tolerated dose of SB-743921 in patients with Non-Hodgkin Lymphoma and Hodgkin Lymphoma. Phase II was intended to asses...
What is the current status of trial NCT00343564?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2006-04. Estimated completion is 2010-07.
What interventions are being tested in trial NCT00343564?
The interventions under investigation include: SB-743921 (DRUG).
Who is sponsoring clinical trial NCT00343564?
This trial is sponsored by Cytokinetics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.